17:57 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

BioCardia's CardiAMP non-significantly improves 6MWD in roll-in cohort of Phase III for heart failure

BioCardia Inc. (OTCQX:BCDA) reported data from the 10-patient roll-in cohort of the Phase III CardiAMP Heart Failure trial to treat heart failure following a heart attack showing that CardiAMP non-significantly improved mean 6-minute walk distance...
22:19 , Jan 4, 2017 |  BC Week In Review  |  Clinical News

CardiAMP: Ph III CardiAMP Heart Failure started

BioCardia began the double-blind, sham-controlled, U.S. Phase III CardiAMP Heart Failure trial to evaluate CardiAMP in up to 260 patients. BioCardia Inc. (Pink:BCDA), San Carlos, Calif.  Product: CardiAMP   Business: Cardiovascular  Molecular target: NA  Description:...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

BioCardia, Tiger X Medical deal

Cardiovascular company BioCardia will reverse-merge with Tiger X Medical. The combined company will retain BioCardia’s name and will continue development of BioCardia’s CardiAMP cell therapy system, which is in Phase II trials to treat heart...